Evaluation of Cognitive State in Seniors Using Neurosteer EEG System

November 16, 2023 updated by: Neurosteer Ltd.

Evaluation of Cognitive State in Seniors Using Neurosteer Single-channel EEG With an Auditory Assessment Tool

This is an observational study. Patients who fulfill all inclusion criteria and none of the exclusion criteria will be enrolled in the study, be neurologically evaluated and will go through EEG recordings while listening to an auditory cognitive assessment tool and preforming tasks. EEG recordings will be analyzed using proprietary computational analyses.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

One of the major problems in the prevention and treatment of neurological disorders, is the lack of cost effective and reliable tools to assess neurodegeneration on a large scale at a very early stage. Although current imaging methods give a clear image of the brain atrophy involved in neurodegenerative disorders, there are deficiencies prohibiting their usage for prevention-scanning of large high-risk population such as high price, long set-up time and the need for trained personnel to conduct the test. Therefore, the development of a reliable tool to assess brain neurodegeneration, associated with cognitive decline independent of personal interpretation and/or variance between clinicians and between medical facilities would be highly valuable. This tool would allow the healthcare team to make appropriate treatment decisions that could aid in neurodegenerative disease prevention.

The Neurosteer system provides objective neurological biomarkers using a wearable easy-to-use affordable system. The system facilitate the capture and interpretation of EEG data with only a single patch of electrodes, attached on the subject's forehead. Neurosteer examination includes completing auditory tasks while measuring brain activity with the device. The data is analyzed using machine learning methods to produce biomarkers, enabling a report of the patient's activity in real time and offline. The examination is easy to preform and can be conducted in every clinic or in patients' homes.

In this study, clinical staff will identify potential subjects and will examine the eligibility of subject according to inclusion and exclusion criteria. Research staff will inform the patient on study's objective and design. Patients will sign the Informed Consent Form (ICF). Research staff will set up an assessment session using the Neurosteer system. In this session the patient will listen to the auditory assessment battery and perform cognitive tasks. Over the next 7 days, clinical staff will set up another session using the Neurosteer system. In this session the patient will listen to auditory instructions and perform two PASS sub-tasks: a drug sorting task and a phone use task.

Level of cognition will be assessed by validated screening tools (MMSE and MoCA) and the Neurosteer technology.

Study Type

Observational

Enrollment (Actual)

77

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Israel
      • Netanya, Israel, 42420
        • Dorot - Netanya Geriatric Medical Center

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

50 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

Yes

Sampling Method

Non-Probability Sample

Study Population

The study population is comprised of patients from the inpatient rehabilitation department at Dorot Geriatric Medical Center.

Description

Inclusion Criteria:

  • Men and women over the age of 50.
  • MMSE ≥ 10
  • Patient is able to collaborate.
  • No seizure events.

Exclusion Criteria:

  • Advanced stage of cognitive decline (MMSE < 10).
  • Any verbal or non-verbal form of objection from patient or form patient's family member or significant other.
  • Significant hearing impairments.
  • Significant vision impairments.
  • Damage to integrity of scalp and/or skull.
  • Skin irritation in the facial and forehead area.
  • Epilepsy or seizure activity.
  • History of drug abuse.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Patients
Patients who are assessed by the clinical staff using Mini-Mental State Exam (MMSE) and Montreal-Cognitive-Assessment-Test(MoCA)
Device: Neurosteer EEG recorder
The system is composed of hardware and software modules that facilitate the capture and interpretation of electrophysiological data as well as enable viewing the processed data in real time and offline. An electrode patch is attached on the subject's forehead to capture the electrophysiological signal. The signal is sent via low energy Bluetooth to an EEG Monitor. The signal is then sent via Wi-Fi to the cloud where the data is stored on a HIPAA compliant server. Data analysis performed in the cloud transforms the electrophysiological signal into easily readable data of brain activity.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Correlation Between Cognition Level Changes as Evaluated by Current Clinical Tools (i.e. MMSE, MoCA) and Brain Activity Features Extracted Using the Neurosteer Technology.
Time Frame: MMSE and MoCA scores will be taken from previous evaluation performed in the institute. Through study completion, brain activity features will be assessed twice within 7 days using the Neurosteer EEG system.

Cognition level changes will be evaluated by:

  1. Mini Mental State Examination (MMSE). A commonly used assessment tool that evaluates cognitive functioning and produces a total possible score of 30 points. Patients who score below 24 are typically suspected of cognitive decline.
  2. Montreal Cognitive Assessment (MoCA). A commonly used assessment tool that evaluates cognitive functioning. The maximum score is 30, with a score of 26 or higher considered cognitively healthy.
  3. Neurosteer system (single channel EEG recording during cognitive auditory tasks).

Using data analysis (a variant of the wavelet packet analysis and the best basis algorithm), the EEG signal is transformed into brain activity features (e.g. ST4, A0).

Pearson correlation will be calculated between the mean activity of the EEG features and individual's MMSE and MoCA scores.
MMSE and MoCA scores will be taken from previous evaluation performed in the institute. Through study completion, brain activity features will be assessed twice within 7 days using the Neurosteer EEG system.

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Reproducibility of the Pilot Study Results
Time Frame: 1 year
In a previous pilot study on a similar population of 50 subjects, biomarkers A0 and ST4 were found to be significantly correlated with MMSE scores. To validate this result, Intra class correlation coefficient (ICC) score will be calculated between the results in the first and second study.
1 year
Differentiation Between Subjects Who Are at Risk for Cognitive Decline and Cognitively Healthy Subjects.
Time Frame: 1 year
In the pilot study, biomarkers A0 and ST4 showed significant ability to differentiate between the group of seniors with cognitive decline (MMSE scores 24-27) and the group of cognitively healthy seniors (MMSE scores 28-30). To reproduce this result, ANOVA will be calculated to determine if there are significant changes between group MMSE scores 24-27 and group MMSE score 28-30, p value<0.05 will be considered significant.
1 year

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Neurosteer Ltd.

Investigators

  • Principal Investigator: Ady Sasson, Dorot, Geriatric Medical Center

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

May 31, 2022

Primary Completion (Actual)

August 27, 2023

Study Completion (Actual)

August 27, 2023

Study Registration Dates

First Submitted

August 29, 2022

First Submitted That Met QC Criteria

August 31, 2022

First Posted (Actual)

September 6, 2022

Study Record Updates

Last Update Posted (Actual)

May 6, 2024

Last Update Submitted That Met QC Criteria

November 16, 2023

Last Verified

August 1, 2022

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 032022

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

Yes

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Cognitive Decline

Clinical Trials on Neurosteer EEG recorder

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Mali

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe